Product Details
| Product Name:
BAY 87-2243 |
CAS No.:
1227158-85-1 |
| Min. Order:
1g |
Purity:
95% |
| Supply Ability:
1KG |
Release date:
2024/10/22 |
| Name:
Cassie Guo |
| BAY 87-2243 Basic information |
| Product Name: |
BAY 87-2243 |
| Synonyms: |
1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine;1-cyclopropyl-4-{4-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)methyl]pyridin-2-yl}piperazine BAY87-2243;BAY 87-2243;1-cyclopropyl-4-{4-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)methyl]pyridin-2-yl}piperazine;CS-1786;BAY87 2243;BAY 87 2243;BAY87-2243 |
| CAS: |
1227158-85-1 |
| MF: |
C26H26F3N7O2 |
| MW: |
525.5255496 |
| EINECS: |
|
| Product Categories: |
Inhibitors |
| Mol File: |
1227158-85-1.mol |
 |
| |
| BAY 87-2243 Chemical Properties |
| Boiling point |
677.7±65.0 °C(Predicted) |
| density |
1.47±0.1 g/cm3(Predicted) |
| pka |
8.43±0.27(Predicted) |
| |
| BAY 87-2243 Usage And Synthesis |
| Enzyme inhibitor |
This Hif1a inhibitor (FW = 525.53 g/mol; CAS 1227158-85-1; Solubility: <1 mg/mL DMSO or H2O) targets the transcription factor hypoxia-inducible factor-1 (HIF-1), which plays an essential role in tumor development, tumor progression, and resistance to chemo- and radiotherapy. BAY 87-2243 inhibits HIF-1α and HIF-2α accumulation under hypoxic conditions in the H460 Non-Small Cell Lung Cancer (NSCLC) cell line but is without effect on HIF-1α protein levels that are induced by such hypoxia mimetics asdesferrioxamine or cobalt chloride. BAY 87-2243 has no effect on HIF target gene expression levels in RCC4 cells lacking Von Hippel-Lindau (VHL) activity; nor does it affect the activity of HIF prolyl hydroxylase-2. Antitumor activity of BAY 87-2243, suppression of HIF-1α protein levels, and reduction of HIF-1 target gene expression in vivo have been demonstrated in a H460 xenograft model. BAY 87-2243 does not inhibit cell proliferation under standard conditions. Upon glucose depletion, a condition favoring mitochondrial ATP generation as energy source, BAY 87-2243 inhibits cell proliferation in the low-nM range. In a mouse model for BRAF mutant melanoma, BAY 87-2243-mediated complex I inhibition induces melanoma cell death in vitro and reduces melanoma tumor growth in various mouse models in vivo. This effect is mediated through BAY 87-2243- induced stimulation of mitochondrial ROS production, leading to oxidative damage and subsequent cell death. BAY 87-2243 displays increased anti tumor efficacy compared to single agent treatment, when combined with the BRAF inhibitor vemurafenib in nude mice with BRAF mutant melanoma xenografts. |
Company Profile Introduction
Technology research and transfer of pilot screening, pilot scale-up and mass production solutions , for pharmaceutical intermediates, biologicals and fine chemicals (Not including inflammable , explosive , hazardous goods ) ; Market : Nano material , metal catalyst , raw material of cosmetics , pharmaceutical intermediates , chemicals , photoelectric material , import and export of technology and goods (For projects subject to approval according to law, business activities can be carried out only after approval by relevant departments ).
You may like
-
-
CAS:910818-29-0
$17.00 / 1g
-
CAS:1260903-17-0
$1.00 / 1g
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$38.00/2mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
|
|
$1.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-21 |
|
|
$277.00/20μg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-18 |
|
|
$1920.00/1mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
![7-Fluoro-imidazo[1,2-a]pyridine](https://img.chemicalbook.com/ProductImageEN/2020-10/Large/23bc17bf-a143-4293-b278-40dfd8c7ab0a.jpg)
China